Drugs / CVM-1118
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04336124 | May 2020 → Feb 2021 | cancer of unknown primary site | TaiRx, Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07521852 | Mar 2026 → Dec 2027 expected | hepatocellular carcinoma | TaiRx, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05257590 | May 2022 → Dec 2026 expected | hepatocellular carcinoma | TaiRx, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT03600233 | Dec 2018 → Sep 2024 overdue | lung neuroendocrine neoplasm, neuroendocrine carcinoma, pancreatic neuroendocrine tumor | TaiRx, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03582618 | Jul 2018 → Nov 2021 | hepatocellular carcinoma | TaiRx, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CVM-1118 | “CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc.” NCT03582618 ↗ |
| Known as | foslinanib | “targets for foslinanib (CVM-1118), which disrupts vasculogenic mimicry and induces apoptosis via tumour necrosis factor receptor-associated protein 1.” PMID 42393461 ↗ Jul 2026 |
| Action | Inhibit | “the ability of inhibiting the VM network make CVM-1118 a potential good combination drug with sorafenib for advanced diseases.” NCT03582618 ↗ |
| Modality | Small molecule | “CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc.” NCT03582618 ↗ |
| Route | Oral | “CVM-1118 will be administered orally at 150 mg BID or 200 mg BID daily” NCT03582618 ↗ |